Natalia Juliá-Palacios,Mireia Olivella,Mariya Sigatullina Bondarenko,Salvador Ibáñez-Micó,Beatriz Muñoz-Cabello,Olga Alonso-Luengo,Víctor Soto-Insuga,Deyanira García-Navas,Laura Cuesta-Herraiz,Patricia Andreo-Lillo,Sergio Aguilera-Albesa,Antonio Hedrera-Fernández,Elena González Alguacil,Rocío Sánchez-Carpintero,Fernando Martín del Valle,Erika Jiménez González,Lourdes Cean Cabrera,Ines Medina-Rivera,Marta Perez-Ordoñez,Roser Colomé,Laura Lopez,María Engracia Cazorla,Montserrat Fornaguera,Aida Ormazabal,Itziar Alonso-Colmenero,Katia Sofía Illescas,Sol Balsells-Mejía,Rosanna Mari-Vico,Maria Duffo Viñas,Gerarda Cappuccio,Gaetano Terrone,Roberta Romano,Filippo Manti,Mario Mastrangelo,Chiara Alfonsi,Bruna de Siqueira Barros,Mathilde Nizon,Cathrine Elisabeth Gjerulfsen,Valeria L Muro,Daniela Karall,Fiona Zeiner,Silvia Masnada,Irene Peterlongo,Alfonso Oyarzábal,Ana Santos-Gómez,Xavier Altafaj,Ángeles García-Cazorla

Abstract:GRIN-related disorders are rare developmental encephalopathies with variable manifestations and limited therapeutic options. Here, we present the first non-randomized, open-label, single-arm trial (NCT04646447) designed to evaluate tolerability and efficacy of L-serine in children with GRIN genetic variants leading to loss-of-function . In this phase 2A trial, patients aged 2–18 years with GRIN loss-of-function pathogenic variants received L-serine for 52-weeks. Primary endpoints included safety and efficacy by measuring changes in the Vineland Adaptive Behavior Scales, Bayley Scales, age-appropriate Wechsler Scales, Gross Motor Function-88, Sleep Disturbance Scale for Children, Pediatric Quality of Life, Child Behavior Checklist and the Caregiver-Teacher Report Form following 12 months treatment. Secondary outcomes included seizure frequency and intensity reduction and electroencephalography improvement. Assessments were performed 3 months and 1 day before starting treatment and 1-3-6-12 months after the beginning of the supplement. Twenty-four participants were enrolled (13 males/11 females, mean age 9.8 years, SD 4.8), 23 of whom completed the study. Patients had GRIN2B , GRIN1 and GRIN2A variants (12, 6 and 5 cases, respectively). Clinical phenotype showed: 91% intellectual disability (61% severe), 83% behavioral problems, 78% movement disorders and 58% with epilepsy. Based on Vineland Adaptive Behavior Composite standard score, nine children were classified as mildly impaired level group (cut-off > 55), whereas 14 were assigned to the clinically severe group. An improvement was detected in Daily Living Skills domain ( P = 0,035) from the Vineland Scales within the mild group. Expressive ( P = 0.005), Personal ( P = 0.003), Community ( P = 0.009), Interpersonal ( P = 0.005) and Fine Motor ( P = 0.031) subdomains improved for the whole cohort, although improvement was mostly found in the mild group. Growth Score Values cognitive subdomain on the Bayley-III showed a significant improvement in the severe group ( P = 0.016), with a mean increase of 21.6 points. L-serine treatment was associated with significant improvement in the median Gross Motor Function-88 total score ( P = 0.002) and the mean Pediatric Quality of Life total score ( P = 0.00068) regardless of severity. L-serine normalized EEG pattern in five children, and the frequency of seizures in one clinically affected child. One patient discontinued treatment due to irritability and insomnia. The trial provides evidence that L-serine is a safe treatment for children with GRIN loss-of-function variants, having the potential to improve the adaptive, motor function and quality of life, with a better response to the treatment in mild phenotypes.

Radiprodil, a selective GluN2B negative allosteric modulator, rescues audiogenic seizures in mice carrying the GluN2A(N615S) mutation

Grin1Y647S/+ Mice: A Preclinical Model of GRIN1-Related Neurodevelopmental Disorder

Grin1 Y 647 S/+ Mice: A Preclinical Model of GRIN1 -Related Neurodevelopmental Disorder

Loss of Grin2a Causes a Transient Delay in the Electrophysiological Maturation of Hippocampal Parvalbumin Interneurons

Characterization of Mice Carrying a Neurodevelopmental Disease-Associated GluN2B(L825V) Variant

Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy

A Sub-Threshold Dose of Pilocarpine Increases Glutamine Synthetase in Reactive Astrocytes and Enhances the Progression of Amygdaloid-Kindling Epilepsy in Rats

Heterogeneous Clinical and Functional Features of GRIN2D-related Developmental and Epileptic Encephalopathy.

N-terminal alternative splicing of GluN1 regulates the maturation of excitatory synapses and seizure susceptibility.

Functional Investigation of a GRIN2A Variant Associated with Rolandic Epilepsy

Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors

GluN2D subunit-containing NMDA receptors regulate reticular thalamic neuron function and seizure susceptibility

Optogenetic stimulation of the superior colliculus suppresses genetic absence seizures

A De Novo Loss-of-function GRIN2A Mutation Associated with Childhood Focal Epilepsy and Acquired Epileptic Aphasia.

Rescuing tri-heteromeric NMDA receptor function: the potential of pregnenolone-sulfate in loss-of-function GRIN2B variants

Delving into the significance of the His289Tyr single-nucleotide polymorphism in the glutamate ionotropic receptor kainate-1 (Grik1) gene of a genetically audiogenic seizure model

Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders

Grin2a Ablation Distinctly Reshapes PV+ and SST+ Interneuron circuits in the Medial Prefrontal Cortex to Amplify Gamma Oscillations

Context-dependent NMDA receptor dysfunction predicts seizure treatment in mice with human GluN1 variant

L-serine treatment in patients with GRIN -related encephalopathy: A phase 2A, non-randomized study

Conventional and novel anti-seizure medications reveal a particular role for GABAA in a North Sea progressive myoclonus Epilepsy Drosophila model